Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Saudi Arabia’s SFDA has approved Leqembi (lecanemab), the Kingdom’s first Alzheimer’s treatment. This innovative drug slows ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to ...

Eisai spokeswoman Libby Holman said prescriptions for Leqembi have been written, and that the company expects patients to begin receiving the drug soon. It will cost about $26,500 for a year of ...